Replies to post #67078 on NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Senti,

I truly think that he would be excited to hear about the advances. If there were one talk you should listen to, and transcribe, it would be this one:

http://www.cancerresearch.org/news-publications/webinars/webinar-george-coukos

On June 17, 2014, George Coukos, M.D., Ph.D., director of the department of oncology at the CHUV, director of the service of developmental therapeutics, and the director of the Ludwig Centre at Lausanne, discussed how current immunotherapy treatment options for women with gynecologic cancers, and how close we are to making these treatments available to more patients.

This 45-minute online webinar, which is part of the Cancer Research Institute's Breakthroughs in Cancer Immunotherapy webinar series, was generously supported by Agenus.

Prior to his current roles, Dr. Coukos was the Celso Ramon Garcia Professor and Associate Chief of the Division of Gynecologic Oncology, and Director, Ovarian Cancer Research Center, at the University of Pennsylvania Abramson Cancer Center. He is a recognized global leader in ovarian cancer immunotherapy and tumor microenvironment research. His research focuses on understanding the immune system's response to ovarian cancer and other tumor types, and on developing therapies that enhance that response. He is also developing tools to target the tumor vasculature. Dr. Coukos also has extensive experience in designing and conducting phase I clinical cell-based immunotherapy studies, and in the development of cell-based immunotherapy from the laboratory to the clinic.

- See more at: http://www.cancerresearch.org/news-publications/webinars/webinar-george-coukos#sthash.8rayXwjz.dpuf

As you are likely aware, Coukos was the lead investigator of DCVax-L Ovarian.

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine Leaded With Autologous Tumor Cell Lysate for Recurrent Ovarian or Primary Peritoneal Cancer

https://clinicaltrials.gov/ct2/show/record/NCT00683241?term=DCVax+Ovarian&rank=2

Make sure you listen to minutes when they specifically discuss DCVax-L, covered 11 - 13.
Whole Tumor lysate being the best approach, personalized antigens. Notice the improvements immunotherapy is having on PFS and overall survival. :)

And make sure you look at slide around the 11:00 point. That clearly shows that yes, DCVax-L patents are in use within the vaccine formulation. That slide makes it quite clear that IL-4 and GM-CSF is used in the vaccine to expand to get DC precursor. BUT, back in 2008, DCVAX-L (ovarian) was pulsed with LPS and INFy. So yeah, their patents are in use. :)

Shortly thereafter the case example of DCVAX-L patient whose, as you may have guessed, survival is on-going. No evidence of disease, and that was after multiple bouts of recurrence, she finally went on DCVax-L therapy. Patient said no to further drugs while in years of remission, feels she doesn't need it. Doctor thinks she's probably right. :)

Just make sure you listen to the entire thing. TIL is covered. Combining with CI is covered. Why it is perceived it will work. And all the various approaches to immunotherapy. Antigens are covered; single epitopes, can lead to multiple types of T-cell response. Mutations. Even listen to Dr. Coukos tell you his thoughts on vaccines, and their place in SoC. It covers everything. Portions around minute 38. Minute 41. Just listen to it all...

and most of all, ENJOY.